دورية أكاديمية
Giant prolactinomas in women
| العنوان: | Giant prolactinomas in women |
|---|---|
| المؤلفون: | Delgrange, Etienne, Raverot, Gerald, Bex, Marie, Burman, Pia, Decoudier, Bénédicte, Devuyst, France, Feldt-Rasmussen, Ulla, Andersen, Marianne, Maiter, Dominique |
| المصدر: | European Journal of Endocrinology ; volume 170, issue 1, page 31-38 ; ISSN 0804-4643 1479-683X |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism |
| الوصف: | Objective To characterise distinctive clinical features of giant prolactinomas in women. Design A multicentre, retrospective case series and literature review. Methods We collected data from 15 female patients with a pituitary tumour larger than 4 cm and prolactin levels above 1000 μg/l and identified 19 similar cases from the literature; a gender-based comparison of the frequency and age distribution was obtained from a literature review. Results The initial PubMed search using the term ‘giant prolactinomas’ identified 125 patients (13 women) responding to the inclusion criteria. The female:male ratio was 1:9. Another six female patients were found by extending the literature search, while our own series added 15 patients. The median age at diagnosis was 44 years in women compared with 35 years in men ( P <0.05). All cases diagnosed before the age of 15 years were boys. In women ( n =34), we observed a minor peak incidence during the third decade of life and a major peak during the fifth decade. Amenorrhoea was a constant feature with seven cases of primary amenorrhoea. In eight women with onset of secondary amenorrhoea before the age of 40 years, the diagnosis was made 2–31 years later (median 9 years) and in all but one because of tumour pressure symptoms. The prolactin levels were above 10 000 μg/l in 15/34 and misdiagnosis due to ‘hook effect’ occurred in two of them. Eighteen patients were treated with cabergoline; standard doses (<2.0 mg/week) were able to normalise prolactin in only 4/18 patients, and 7/18 patients were resistant to weekly doses ranging from 3.0 to 7.0 mg. Conclusion Giant prolactinomas are rare in women, often resistant to dopamine agonists and seem to be distributed in two age groups, with a larger late-onset peak. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| DOI: | 10.1530/eje-13-0503 |
| الإتاحة: | https://doi.org/10.1530/eje-13-0503Test https://eje.bioscientifica.com/view/journals/eje/170/1/31.xmlTest |
| رقم الانضمام: | edsbas.33308392 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1530/eje-13-0503 |
|---|